Cross-protection from human papillomavirus 16/18 against types 45 and 31: fact or fancy?

Author： Nishida Karen J   Pearson J Matthew   Twiggs Leo B  

Publisher： Future Medicine

ISSN： 1475-0708

Source： Therapy, Vol.5, Iss.3, 2008-05, pp. : 265-268

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Individual and geographic disparities in human papillomavirus types 16/18 in high‐grade cervical lesions

By  

CANCER, Vol. 119, Iss. 16, 2013-08 ,pp. : 3052-3058

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cross-Protection against Homologous Drift Variants of Influenza A and B after Vaccination with Split Vaccine

By  

Intervirology, Vol. 50, Iss. 1, 2006-11 ,pp. : 58-62

Karger

Access to resources Recommend Favorite

Salivary Mucoepidermoid Carcinoma: Demonstration of Transcriptionally Active Human Papillomavirus 16/18

By Isayeva Tatyana  

Head and Neck Pathology, Vol. 7, Iss. 2, 2013-06 ,pp. : 135-148

Humana Press, Inc

Access to resources Recommend Favorite

Human Papillomavirus 16/18 Infections in Lung Cancer Patients in Mexico

By  

Intervirology, Vol. 56, Iss. 5, 2013-08 ,pp. : 310-315

Karger

Access to resources Recommend Favorite

Protection of Mice by a λ-Based Therapeutic Vaccine against Cancer Associated with Human Papillomavirus Type 16

By  

Intervirology, Vol. 54, Iss. 3, 2010-10 ,pp. : 105-112

Karger

Access to resources Recommend Favorite